CD7
Showing 26 - 50 of >10,000
CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies Trial in Hefei (T cell injection targeting CD7 chimeric
Recruiting
- CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies
- T cell injection targeting CD7 chimeric antigen receptor
-
Hefei, Anhui, ChinaPersonGen.Anke Cellular Therapeutice Co., Ltd.
Dec 24, 2021
Refractory and Relapsed T Cell Lymphoma Trial in Suzhou (Humanized CD7 CAR-T cells)
Recruiting
- Refractory and Relapsed T Cell Lymphoma
- Humanized CD7 CAR-T cells
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University
Sep 17, 2021
Hematologic Malignancies Trial in Hangzhou (RD13-01 cell infusion)
Completed
- Hematologic Malignancies
- RD13-01 cell infusion
-
Hangzhou, Zhejiang, ChinaThe First Affiliated Hospital，College of Medicine, Zhejiang Univ
Jan 8, 2022
T-Cell Lymphocytic Leukemia, T-Cell Chronic Lymphocytic Leukemia, T Cell Non-Hodgkin Lymphoma Trial in Wuhan (Fludarabine +
Recruiting
- T-Cell Lymphocytic Leukemia
- +2 more
- Fludarabine + Cyclophosphamide + CAR7-T Cells
-
Wuhan, Hubei, ChinaUnion Hospital, Huazhong University of Science and Technology
Mar 1, 2022
T Cell Lymphoblastic Lymphoma Trial in Beijing (BT-007 CD7 CAR-T cells)
Recruiting
- T Cell Lymphoblastic Lymphoma
- BT-007 CD7 CAR-T cells
-
Beijing, ChinaBeijing Cancer Hospital
Sep 22, 2022
T-cell Acute Lymphoblastic Leukemia/Lymphoma Trial in Yanda (CD7 CAR-T)
Completed
- T-cell Acute Lymphoblastic Leukemia/Lymphoma
- CD7 CAR-T
-
Yanda, Hebei, ChinaHebei yanda Ludaopei Hospital
Jun 23, 2021
T Lymphoblastic Leukemia/Lymphoma, Mixed Phenotype Acute Leukemia, Acute Myeloid Leukemia Trial in Suzhou (Humanized CD7 CAR-T
Recruiting
- T Lymphoblastic Leukemia/Lymphoma
- +2 more
- Humanized CD7 CAR-T cells
-
Suzhou, (Select), ChinaThe First Affiliated Hospital of Soochow University
Jun 1, 2021
SenL-T7 CAR T Cells for CD7+ T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma Trial in Beijing (Senl-T7)
Recruiting
- SenL-T7 CAR T Cells for CD7+ T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
- Senl-T7
-
Beijing, Hebei, ChinaHebei yanda Ludaopei Hospital
Jun 23, 2021
Idiopathic CD4 Lymphopenia Trial run by the National Institute of Allergy and Infectious Diseases (NIAID) (Recombinant human
Not yet recruiting
- Idiopathic CD4 Lymphopenia
- Recombinant human interleukin (IL) 7-hyFc
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Feb 2, 2023
T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma, T-cell Non-Hodgkin Lymphoma Trial in Shenzhen (CD7 CAR
Recruiting
- T-cell Acute Lymphoblastic Leukemia
- +2 more
- CD7 CAR T cells
-
Shenzhen, Guangdong, ChinaPeking University Shenzhen Hospital
Jun 19, 2021
Psoriasis Trial in Sohag (skin biopsy)
Not yet recruiting
- Psoriasis
- skin biopsy
-
Sohag, EgyptSohag university Hospital
Sep 21, 2023
T-cell Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma Trial in Australia, United States (WU-CART-007)
Recruiting
- T-cell Acute Lymphoblastic Leukemia
- Lymphoblastic Lymphoma
- WU-CART-007
-
Duarte, California
- +7 more
Jun 22, 2022
T-cell Leukemia, T-cell Lymphoma Trial in ChongQing (CD7 UCAR-T cells, Fludarabine, Cytoxan)
Recruiting
- T-cell Leukemia
- T-cell Lymphoma
- CD7 UCAR-T cells
- +3 more
-
ChongQing, Chongqing, ChinaDepartment of Hematology, Xinqiao Hospital
Jun 21, 2021
T-ALL Trial in Suzhou (T cell injection targeting CD7 chimeric antigen receptor)
Recruiting
- T-ALL
- T cell injection targeting CD7 chimeric antigen receptor
-
Suzhou, Jiangsu, ChinaThe First Affiliared Hospital Of SOOCHOW University
Mar 3, 2021
Diffuse Large B-cell Lymphoma Trial in Hangzhou, Ningbo (CD19-7×19 CAR-T combined with Tislelizumab)
Recruiting
- Diffuse Large B-cell Lymphoma
- CD19-7×19 CAR-T combined with Tislelizumab
-
Hangzhou, Zhejiang, China
- +1 more
Dec 12, 2022
Study for Patients Treat With WU-CART-007
Enrolling by invitation
- T-cell Acute Lymphoblastic Leukemia
- T-cell Lymphoblastic Lymphoma
- Genetic: WU-CART-007
-
Saint Louis, MissouriWashington University
Aug 18, 2022
T-Acute Lymphoblastic Leukemia, T-cell Non-Hodgkin Lymphoma, T-cell Acute Lymphoblastic Lymphoma Trial in Hefei, Suzhou
Recruiting
- T-Acute Lymphoblastic Leukemia
- +2 more
- ThisCART7 cells
-
Hefei, Anhui, China
- +1 more
Nov 9, 2021
Lymphoblastic Lymphoma, T-Cell Lymphoblastic Leukemia/Lymphoma, Lymphoblastic Leukemia Trial in Philadelphia (BEAM-201)
Recruiting
- Lymphoblastic Lymphoma
- +2 more
- BEAM-201
-
Philadelphia, PennsylvaniaChildren's Hospital of Philadelphia
Jun 2, 2023
Safety and Efficacy Trial in Suzhou (Basiliximab, Vedolizumab)
Recruiting
- Safety and Efficacy
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University
Sep 27, 2023
T Lymphoblastic Leukemia/Lymphoma, Extramedullary NK-T-cell Lymphoma, Nasal Type, Peripheral T-cell Lymphoma, Nonspecific Trial
Recruiting
- T Lymphoblastic Leukemia/Lymphoma
- +6 more
- T cell injection targeting CD7 chimeric antigen receptor
-
Zhengzhou, Henan, ChinaFirst Affiliated Hospital of Zhengzhou University
Jan 4, 2021
CAR, Malignant Tumors Trial in Hefei (Chimeric antigen receptor modified ?d T cells)
Recruiting
- CAR
- Malignant Tumors
- Chimeric antigen receptor modified γδ T cells
-
Hefei, Anhui, ChinaAnhui Provincial Hospital
Mar 4, 2021
Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Leukemia, Lymphoblastic Leukemia, Acute Adult Trial in Singapore (CAR
Recruiting
- Lymphoblastic Leukemia, Acute, Childhood
- +6 more
- CAR T-cell therapy
-
Singapore, SingaporeAllen Yeoh Eng Juh
Sep 7, 2021
Relapsed Non Hodgkin Lymphoma, Relapsed Adult ALL, Relapsed Pediatric ALL Trial in Calgary, Edmonton (autologous CD19-directed
Recruiting
- Relapsed Non Hodgkin Lymphoma
- +2 more
- autologous CD19-directed chimeric antigen receptor (CAR) T-cells
-
Calgary, Alberta, Canada
- +5 more
Jul 18, 2022
Multiple Myeloma Trial in Charlottesville (SLAMF7 BATs)
Not yet recruiting
- Multiple Myeloma
- SLAMF7 BATs
-
Charlottesville, VirginiaUniversity of Virginia
May 17, 2022